NVAX - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan Novavax Corp

Novavax, Inc. (NVAX) experiences unstable cash flows dependent on government contracts, yet its status as a defensive asset during recessions ensures an inflow of funds. Quarterly EPS variation illustrates this balance, and 84.60 becomes the new value for this metric. Profit dynamics are subject to strong autumn seasonality and regulatory risks, rendering the final financial results volatile.

Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan Novavax (NVAX): kanggo periode 04.07.2022 - 15.11.2026

Rincian analitis perusahaan Novavax, Inc.

- nilai pasar lan prakiraan target analis:

Bagan rega Novavax Corp|NVAX - Konsensus nilai wajar

- statistik kapitalisasi pasar:

Biji pasar Novavax Pharma|NVAX - Nilai Perusahaan

- indikator kapitalisasi buku:

Aset Bersih saben Siji Saham Novavax|NVAX - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku novavax.com|NVAX - Total Aset Bisnis

- data utang lan likuiditas:

- rincian bathi lan kelipatan pasar:

NVAX - Bathi resik|Bathi mangsa ngarep Novavax, Inc.|NVAX - Pangali rega marang bathi|Prakiraan rega marang bathi Novavax, Inc.|NVAX - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Novavax Inc|NVAX - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Novavax|NVAX - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan novavax.com|NVAX - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Novavax, Inc.

- data dodolan lan asil:

NVAX - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan Novavax, Inc.|NVAX - Rasio kapitalisasi marang pendapatan|Multiplikator forward rega marang pendapatan Novavax|NVAX - Wutah dodolan YoY sajrone rolas wulan kepungkur

Pambiji fundamental:Novavax Inc - NVAX

For Novavax, Inc. (NVAX), quarterly EPS growth serves as an indicator of the actual efficiency of earnings per share generation. The quarterly EPS growth trajectory on GURU.Markets reflects the percentage change in net income, adjusted for one-time factors. This metric measures the recovery rate of business profitability. For the vaccine manufacturer, this is a critical marker of the ability to overcome liquidity shortages and production disruptions. The trend of this indicator determines the company's viability in competition with pharma behemoths.

Analisis pesaing